Four days post-implantation, these tumor-bearing mice were randomly divided into three groups and treated with DCLK1-IN-1 via oral gavage (20 mg/kg, every other day), S31-201 intraperitoneally (5 mg/kg, three times a week) and the corresponding solvent, respectively. Here, DCLK1 is linked to neoplasm.